The Age of Brain Investing Is Here — The $11 Billion 'Brain Wealth' Industry Is Coming for What's Inside Your Skull

In the short term, over the next one to six months, the Brain Wealth market will hit the accelerator. The second half of 2026 is expected to see a parade of new wearable neurotech product launches from major tech companies. Industry rumors persist that Apple may integrate brainwave monitoring into AirPods, and Samsung is reportedly considering cognitive function tracking in follow-up models to the Galaxy Ring. With startups like Mave Health entering the market on $2.1 million seed rounds, multiple sub-$100 mass-market neurofeedback devices are likely to appear among Amazon bestsellers by late 2026. In the nootropics space, AI-powered personalized cognitive subscription services are poised for explosive growth across the US and Europe, supported by the stress relief segment's 14.6% annual growth rate. The caution flag for this period, however, is over-marketing. A proliferation of unverified nootropic brands is expected, and a consumer trust crisis could become the first real test.

In the medium term, six months to two years out, three significant transitions are predicted. First, the global spread of the Brain Capital Index. The adoption that began in the Nordics in early 2026 is likely to expand to innovation-oriented nations like Canada, Singapore, and South Korea by 2027. Canada is already engaged in policy discussions to make brain capital a new pillar for its innovation economy, and South Korea's combination of intense educational ambition and mental health crisis creates substantial demand for brain capital policy. Second, consolidation of the wearable neurotech market. The currently fragmented landscape of small neurotech startups will begin restructuring through acquisitions by Big Tech players like Apple, Google, and Samsung, or through attrition. With 64% of companies in the consumer EEG segment already using this technology, differentiation is increasingly difficult, inevitably leading to an M&A wave. Third, the emergence of regulatory frameworks. As the regulatory vacuum around neurofeedback devices and cognitive enhancement supplements becomes a social issue, the EU is expected to proactively propose regulations related to Neuro Rights. GDPR-level regulations governing the collection, storage, and use of brain data could take shape by the end of 2027.

In the long term, looking two to five years ahead, three scenarios emerge. In the Bull Case, the Brain Capital Index is adopted by 30+ countries, neurotech prices fall to smartwatch levels, and cognitive health management becomes as routine as taking your temperature. The brain health supplement market surpasses $40 billion by 2030, and the wearable neurotech market reaches $5.34 billion. The convergence of AI and neurotech pushes early Alzheimer's detection rates above 80%, dramatically reducing dementia-related social costs and entering the trajectory of McKinsey's projected $6.2 trillion GDP gains. In the Base Case, the market grows steadily but at a moderated pace due to regulatory uncertainty and the limits of scientific validation. Neurotech wearables occupy a position similar to fitness trackers, and brands previously hidden behind initial hype begin to be culled. The Brain Capital Index is adopted by 10-15 countries, but tangible policy effects remain limited. Notably, even in this scenario, the brain health supplement market reaches $13.69 billion by 2034, meaning the base case still presupposes significant growth. In the Bear Case, large-scale reports of health damage from unverified nootropics collapse trust in the entire market. A wave of lawsuits over neurofeedback device malfunctions and a brain data breach scandal prompt regulators to tighten aggressively. Even in this scenario, awareness of brain health importance does not retreat, but private market growth decelerates sharply and may reorganize around hospitals and public healthcare systems.

Regardless of which scenario materializes, one thing is certain: the trajectory of brain health ascending from an individual's optional wellness activity to social infrastructure is irreversible. The question is whether this massive transition will be designed to benefit everyone, or become yet another engine of inequality. If we take Fortune's warning seriously that the global cost of brain health disorders will reach $16 trillion by 2030, we don't have much time to defer the answer.